BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 466 filers reported holding BIO-TECHNE CORP in Q1 2021. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,887,141 | -10.2% | 365,611 | +7.7% | 3.40% | +13.8% |
| Q2 2023 | $27,720,813 | +22.5% | 339,591 | +11.3% | 2.99% | +20.7% |
| Q1 2023 | $22,628,321 | -15.7% | 305,005 | -5.9% | 2.47% | -13.9% |
| Q4 2022 | $26,851,131 | +26.8% | 323,976 | +334.6% | 2.87% | +22.2% |
| Q3 2022 | $21,172,000 | -19.4% | 74,550 | -1.7% | 2.35% | -13.5% |
| Q2 2022 | $26,276,000 | -20.4% | 75,804 | -0.6% | 2.72% | -1.6% |
| Q1 2022 | $33,019,000 | -14.2% | 76,250 | +2.5% | 2.76% | -2.1% |
| Q4 2021 | $38,471,000 | +5.0% | 74,363 | -1.6% | 2.82% | +2.1% |
| Q3 2021 | $36,624,000 | +8.2% | 75,581 | +0.6% | 2.76% | +4.1% |
| Q2 2021 | $33,834,000 | +16.8% | 75,144 | -0.9% | 2.65% | +10.1% |
| Q1 2021 | $28,958,000 | +45.0% | 75,820 | +20.6% | 2.41% | +43.8% |
| Q4 2020 | $19,971,000 | +32.7% | 62,892 | +3.5% | 1.68% | +2.1% |
| Q3 2020 | $15,051,000 | – | 60,755 | – | 1.64% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |